A Phase 2 interventional study of Tacrolimus 0.03% ointment (Protopic) in Allergic Conjunctivitis, sponsored by Assaf-Harofeh Medical Center. Status unknown at 1 site in Israel. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2007-03-05.
Sponsored by Assaf-Harofeh Medical Center · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.
361 studies on the registry are indexed under Conjunctivitis; 17 are open to participants now.
Browse Conjunctivitis studies →Assaf-Harofeh Medical Center is the lead sponsor of 258 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This study is status unknown, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assaf-Harofeh Medical Center